Literature DB >> 12919746

Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection.

Siddhartha Mahanty1, Manisha Gupta, Jason Paragas, Mike Bray, Rafi Ahmed, Pierre E Rollin.   

Abstract

A mouse-adapted strain of Ebola Zaire virus produces a fatal infection when BALB/cj mice are infected intraperitoneally (ip) but subcutaneous (sc) infection with the same virus fails to produce illness and confers long-term protection from lethal ip rechallenge. To identify immune correlates of protection in this model, we compared viral replication and cytokine/chemokine responses to Ebola virus in mice infected ip (10 PFU/mouse), or sc (100 PFU/mouse) and sc "immune" mice rechallenged ip (10(6) PFU/mouse) at several time points postinfection (pi). Ebola viral antigens were detected in the serum, liver, spleen, and kidneys of ip-infected mice by day 2 pi, increasing up to day 6. Sc-infected mice and immune mice rechallenged ip had no detectable viral antigens until day 6 pi, when low levels of viral antigens were detected in the livers of sc-infected mice only. TNF-alpha and MCP-1 were detected earlier and at significantly higher levels in the serum and tissues of ip-infected mice than in sc-infected or immune mice challenged ip. In contrast, high levels of IFN-alpha and IFN-gamma were found in tissues within 2 days after challenge in sc-infected and immune mice but not in ip-infected mice. Mice became resistant to ip challenge within 48 h of sc infection, coinciding with the rise in tissue IFN-alpha levels. In this model of Ebola virus infection, the nonlethal sc route of infection is associated with an attenuated inflammatory response and early production of antiviral cytokines, particularly IFN-alpha, as compared with lethal ip infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919746     DOI: 10.1016/s0042-6822(03)00233-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  39 in total

1.  Robust and sustained immune activation in human Ebola virus infection.

Authors:  Judith N Mandl; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-07       Impact factor: 11.205

2.  Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism.

Authors:  Shridhar Bale; Jean-Philippe Julien; Zachary A Bornholdt; Alexander S Krois; Ian A Wilson; Erica Ollmann Saphire
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

3.  Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

Authors:  St Patrick Reid; Charalampos Valmas; Osvaldo Martinez; Freddy Mauricio Sanchez; Christopher F Basler
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Ebola Virus Replication and Disease Without Immunopathology in Mice Expressing Transgenes to Support Human Myeloid and Lymphoid Cell Engraftment.

Authors:  Jessica R Spengler; Kerry J Lavender; Cynthia Martellaro; Aaron Carmody; Andreas Kurth; James G Keck; Greg Saturday; Dana P Scott; Stuart T Nichol; Kim J Hasenkrug; Christina F Spiropoulou; Heinz Feldmann; Joseph Prescott
Journal:  J Infect Dis       Date:  2016-09-06       Impact factor: 5.226

5.  Sindbis Virus Can Exploit a Host Antiviral Protein To Evade Immune Surveillance.

Authors:  Xinlu Wang; Melody M H Li; Jing Zhao; Shenglan Li; Margaret R MacDonald; Charles M Rice; Xiang Gao; Guangxia Gao
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

6.  Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.

Authors:  Gene G Olinger; Michael A Bailey; John M Dye; Russell Bakken; Ana Kuehne; John Kondig; Julie Wilson; Robert J Hogan; Mary Kate Hart
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  Antiviral activity of a small-molecule inhibitor of filovirus infection.

Authors:  Travis K Warren; Kelly L Warfield; Jay Wells; Sven Enterlein; Mark Smith; Gordon Ruthel; Abdul S Yunus; Michael S Kinch; Michael Goldblatt; M Javad Aman; Sina Bavari
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

8.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.

Authors:  Daisy W Leung; Kathleen C Prins; Dominika M Borek; Mina Farahbakhsh; JoAnn M Tufariello; Parameshwaran Ramanan; Jay C Nix; Luke A Helgeson; Zbyszek Otwinowski; Richard B Honzatko; Christopher F Basler; Gaya K Amarasinghe
Journal:  Nat Struct Mol Biol       Date:  2010-01-17       Impact factor: 15.369

9.  A Syrian golden hamster model recapitulating ebola hemorrhagic fever.

Authors:  Hideki Ebihara; Marko Zivcec; Donald Gardner; Darryl Falzarano; Rachel LaCasse; Rebecca Rosenke; Dan Long; Elaine Haddock; Elizabeth Fischer; Yoshihiro Kawaoka; Heinz Feldmann
Journal:  J Infect Dis       Date:  2012-10-08       Impact factor: 5.226

10.  Ebola virus-like particles protect from lethal Ebola virus infection.

Authors:  Kelly L Warfield; Catharine M Bosio; Brent C Welcher; Emily M Deal; Mansour Mohamadzadeh; Alan Schmaljohn; M Javad Aman; Sina Bavari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.